Cardiac risk test using breast cancer radiotherapy scans to guide decisions
Official title: ARTILLERY-CarDI, Early Detection of Non-communicable Disease Risk in People With Breast Cancer: Multicenter Cardiac Decision Impact Study
Run by UMC Utrecht · NCT07703033 · Data updated 2026-11-12
This study tests whether checking coronary artery calcium on planning CT scans can help patients with breast cancer make informed heart-risk decisions during radiotherapy planning.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | UMC Utrecht Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Copenhagen and 4 other locations) |
| Status | Recruiting |
| Started | April 20, 2026 |
| Main results expected | May 1, 2028 |
| Study ends | May 1, 2028 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT07703033 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women with breast cancer or DCIS, aged 35 or older, who are planned to receive radiotherapy and can provide informed consent.
✕Probably not a fit
Patients without significant coronary calcifications or with limited life expectancy may not experience meaningful cardiovascular risk changes from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter interventional study uses routine radiotherapy planning CT scans to measure coronary artery calcifications and communicates the associated cardiovascular risk to patients. The goal is to see how this information affects patients’ understanding and decisions about their treatment. The trial involves women with breast cancer (or DCIS) who are planned for radiotherapy and are 35 or older. Results will inform whether incorporating CAC assessment into planning improves patient-centered care and decision quality. No results are reported yet since the study design is to observe the impact of this communication strategy.
Why it matters
Potential benefit: If successful, patients may make more informed choices about their treatment and cardiovascular risk management.
How similar studies have gone: Previous work suggests that sharing imaging-based cardiovascular risk information can influence patient decisions, though this exact CAC-based communication during RT planning is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed with breast cancer or ductal carcinoma in situ * Planned for radiotherapy * From 35 years of age onwards Exclusion Criteria: * Pregnancy * Breastfeeding
Where it's running
-
St. Antonius Hospital
Utrecht, Netherlands Recruiting -
RegionH
Copenhagen, Denmark Not yet recruiting -
LMU University Hospital
München, Germany Not yet recruiting -
Amsterdam University Medical Center
Amsterdam, Netherlands Not yet recruiting -
Champalimaud Foundation
Lisbon, Portugal Not yet recruiting
Study contacts
- Study coordinator: Verkooijen
- Email: cardi@umcutrecht.nl
- Phone: +31 (0) 88 755 6689
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Weight management program for breast cancer survivors in rural communities
This program will test whether a 12-week remote WeCan-Rural program helps rural breast cancer survivors with obesity lose weight, ease symptoms, and lower heart disease risk.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
Air filters at home to see if breathing cleaner air helps heart health in obesity
This study tests whether portable air filtration systems can improve cardiovascular risk factors in adults with obesity and high blood pressure.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.